Order Article Reprints

Murata R, Watanabe H, Nosaki H, Nishida K, Maeda H, Nishida M, Maruyama T. Long-Acting Thioredoxin Ameliorates Doxorubicin-Induced Cardiomyopathy via Its Anti-Oxidative and Anti-Inflammatory Action. Pharmaceutics. 2022; 14(3):562. https://doi.org/10.3390/pharmaceutics14030562

Murata, Ryota, Hiroshi Watanabe, Hiroto Nosaki, Kento Nishida, Hitoshi Maeda, Motohiro Nishida, and Toru Maruyama. 2022. "Long-Acting Thioredoxin Ameliorates Doxorubicin-Induced Cardiomyopathy via Its Anti-Oxidative and Anti-Inflammatory Action" Pharmaceutics 14, no. 3: 562. https://doi.org/10.3390/pharmaceutics14030562

Murata, R., Watanabe, H., Nosaki, H., Nishida, K., Maeda, H., Nishida, M., & Maruyama, T. (2022). Long-Acting Thioredoxin Ameliorates Doxorubicin-Induced Cardiomyopathy via Its Anti-Oxidative and Anti-Inflammatory Action. Pharmaceutics, 14(3), 562. https://doi.org/10.3390/pharmaceutics14030562